Enoxaparin for the long-term therapy of venous thromboembolism in patients with cancer and renal insufficiency.

Patricia SigüenzaJuan José López-NúñezConcepción Falga TiradoCovadonga Gómez-CuervoAntoni Riera-MestreAída Gil-Díaz Peter VerhammeAna Cristina MontenegroCristina Barbagelata-LópezEgidio ImbalzanoManuel Monreal

Published in: Thrombosis and haemostasis (2023)

Among cancer patients with severe RI, fatal PE was 5-fold more common than fatal bleeding. The recommended doses of enoxaparin in these patients should be revisited.

Keyphrases

venous thromboembolism
end stage renal disease
direct oral anticoagulants
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
papillary thyroid
squamous cell carcinoma
stem cells
mesenchymal stem cells
bone marrow